Which of the following drugs inhibit bacterial beta-lactamase?

A. Ototoxicity:

Ototoxicity refers to damage to the auditory and vestibular nerves, leading to hearing loss and balance disturbances. Gentamicin, being an aminoglycoside antibiotic, is known for its potential to cause ototoxicity. Signs and symptoms of ototoxicity include changes in hearing, ringing in the ears (tinnitus), and imbalance. Ototoxicity is irreversible and can occur suddenly or gradually during gentamicin therapy. Therefore, any signs or symptoms of ototoxicity should be reported immediately to the physician for further evaluation and management.

B. Nausea:

Nausea is a common gastrointestinal side effect associated with gentamicin therapy. While it can be bothersome to the patient, nausea alone is not typically considered a severe adverse effect that requires immediate reporting to the physician. However, if nausea is severe or persistent and leads to dehydration or electrolyte imbalances, it should be addressed promptly.

C. Constipation:

Constipation is another potential gastrointestinal side effect of gentamicin therapy. Like nausea, constipation alone is not typically considered a severe adverse effect that requires immediate reporting to the physician. However, if constipation is severe or persistent and leads to discomfort or bowel obstruction, it should be addressed promptly.

D. Increased urinary output:

Increased urinary output may indicate improved renal function, which can be a desired effect during gentamicin therapy. Gentamicin is primarily excreted by the kidneys, and increased urinary output may help in the elimination of the drug from the body. Therefore, increased urinary output alone is not typically considered an adverse effect that requires immediate reporting to the physician. However, if there are signs of dehydration or electrolyte imbalances associated with increased urinary output, they should be addressed promptly.

A. Immunocompromised patients:

Immunocompromised patients, whose immune systems are weakened or impaired, are indeed more vulnerable to drug toxicity. This vulnerability can be due to factors such as decreased ability to metabolize and eliminate drugs, increased susceptibility to infections and opportunistic pathogens, and impaired organ function, particularly in the liver and kidneys, which are involved in drug metabolism and excretion.

B. Immunocompetent patients:

Immunocompetent patients have normal immune function and are generally less vulnerable to drug toxicity compared to immunocompromised individuals. However, susceptibility to drug toxicity can still vary depending on factors such as age, underlying health conditions, renal and hepatic function, and concurrent use of other medications.

C. Infants and elderly patients:

Infants and elderly patients are more vulnerable to drug toxicity due to factors such as immature or declining organ function, altered drug metabolism and elimination, and differences in body composition. In infants, organ systems are still developing, while in elderly patients, age-related changes can affect drug pharmacokinetics and increase the risk of adverse reactions.

D. Patients who have allergic reactions:

Patients who have allergic reactions may experience adverse drug reactions if they are exposed to the offending medication again. However, this does not necessarily make them more vulnerable to drug toxicity in general. Allergic reactions are specific immune responses and differ from drug toxicity, which can occur due to various mechanisms unrelated to allergies.